Hidradenitis suppurativa (HS) is a multifocal chronic inflammatory condition characterized by recurrent painful nodules, abscesses, and scarring predominantly in intertriginous areas, significantly impairing patients’ physical and mental health. Despite its profound impact, HS often remains undiagnosed for years, emphasizing the need for heightened clinical awareness. This review explores the latest advancements in the management of HS, providing an overview of current therapeutic strategies, emerging treatments, and associated challenges. Traditional treatments—including topical agents, antibiotics, and hormonal therapies—aim to manage symptoms and prevent progression. The introduction of Food and Drug Administration–approved biologics, such as adalimumab, secukinumab, and bimekizumab, has transformed care by targeting underlying inflammatory mechanisms. Emerging therapies, including Janus kinase inhibitors and novel monoclonal antibodies, demonstrate promising results in mitigating disease severity and improving quality of life. This review also highlights surgical interventions and the importance of lifestyle modifications in comprehensive care. Given the complex and heterogeneous nature of HS, a multidisciplinary approach integrating dermatological, surgical, and psychological care is essential. While significant progress has been made, ongoing research is crucial to addressing unmet needs, optimizing treatment outcomes, and enhancing the lives of individuals affected by this debilitating disease.
Patel et al. (Thu,) studied this question.